Aurealis Therapeutics to present at Swiss Nordic Bio 2018

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018.

The presentation is scheduled for:

  • Time: Thursday, February 8th 2018 at 10:55 am.
  • Location: Renaissance Zurich Tower Hotel, Room: Bavaria B.

“We are looking forward to this intensive one day partnering and investor event, Swiss Nordic Bio 2018. We will present and speak with investors and pharma about our chronic wound product AUP-16, which is in clinical trial application filing stage. We will also update the audience on our pre-clinical programs on cancer and osteoarthritis” said CEO Juha Yrjänheikki.

About Swiss Nordic Bio

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio carries 12 years of tradition, previously Swiss Scandinavian Bio-Business Seminar, and is organized by the Nordic countries in cooperation with Swiss partners.

About Aurealis Therapeutics

Aurealis Therapeutics AG is a Swiss-Finnish private clinical-stage biopharmaceutical company focusing on the development of the clinical asset AUP-1602, the first-in-class four-in-one combination biologic drug for chronic wounds and other chronic inflammatory and degenerative diseases. The product is based on proprietary technology where genetically engineered lactic acid bacteria act as millions of small immune activating bioreactors in the human tissue and produce multiple human therapeutic proteins into the target tissue to effectively and safely re-educate the distorted host immune microenvironment to a proper state.

For more information:

Juha Yrjänheikki, CEO

Tel: +358 45 8433550

Email: juha(at)

Share the news:

other recent news: